The phase 3 IMpactMF study will be discontinued after an independent committee determined it was unlikely to meet its primary end point of overall survival.
|Videos|December 15, 2017
Glasdegib Active in Heavily Pretreated Myelofibrosis
Author(s)Aaron Gerds, MD
This video reviews the phase I portion of a trial testing glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
Advertisement
In this video, Aaron Gerds, MD, of the Cleveland Clinic in Ohio, discusses the phase I portion of a phase I/II trial testing the smoothened (SMO) inhibitor glasdegib in patients with primary/secondary myelofibrosis previously treated with JAK inhibitors.
Gerds gave a presentation on this study (
Advertisement
Related to this article
Oral vitamin C improved OS in patients with CCUS or lower-risk myeloid malignancies in the EVITA trial despite missing the clonal growth primary end point.
Advertisement
Advertisement
Trending on CancerNetwork
1
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
2
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5